Atracurium is a non-depolarizing neuromuscular blocking agent used for intubation and muscle relaxation during surgery. It has a quaternary ammonium structure and acts by competitively binding to nicotinic receptors at the motor end plate. Atracurium has a moderately rapid onset and duration of action. It is metabolized rapidly by Hofmann elimination and ester hydrolysis in the liver and excreted in urine. Common side effects include hypotension, tachycardia, and potential allergic reactions.
5. PHARMACOKINETICS
? Bioavailability: poorly absorbed from the GI
tract
? Half-life: approximately 20 minutes
? Distribution: into extracellular fluid, minimally
crosses the placenta
? Elimination Route: excreted principally in
urine and also in feces via biliary elimination
9. METABOLISM AND EXCRETION
Ester Hydrolysis
This action is catalyzed by nonspecific esterases
Hofmann Elimination
A spontaneous non-enzymatic chemical breakdown
occurs at physiological pH and temperature.
10. DOSAGE AND ADMINISTRATION
? A dose of 0.5 mg/kg is administered
intravenously for intubation
? incremental doses of 0.1 mg/kg every 10C20
min after administration of succinylcholine
? An infusion of 5C10 mcg/kg/min can
effectively replace intermittent boluses
13. CLINICAL SIDE EFFECTS
Hypotension and Tachycardia
Bronchospasm
Laudanosine Toxicity
Temperature and pH Sensitivity
Chemical Incompatibility
Allergic Reactions